Brief: PhaseRx receives orphan drug designation from FDA for PRX-OTC
28/11/2016 13:30
Nov 28 (Reuters) - PhaseRx Inc PZRX.O -
* Phaserx receives orphan drug designation from FDA for
PRX-OTC for the treatment of ornithine transcarbamylase
deficiency
* PRX-OTC, which is being developed for treatment of
ornithine transcarbamylase deficiency has received orphan drug
designation by U.S. FDA
Source text for Eikon: ID:nPn8QMKRXa
Further company coverage: PZRX.O
((Bangalore.newsroom@thomsonreuters.com))
Recent news on PZ Wind Down
See all newsBrief: Phaserx, Roivant Enter Into Asset Purchase Agreement
Brief: Phaserx Says Auction For Nearly All Of Co's Assets Was Held, But Did Not Conclude
Brief: Phaserx Revokes Proposed Distribution Record Date
Brief: PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares
Brief: Phaserx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding